1. Home
  2. SUPX vs SLN Comparison

SUPX vs SLN Comparison

Compare SUPX & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Super X AI Technology Limited Ordinary Shares

SUPX

Super X AI Technology Limited Ordinary Shares

HOLD

Current Price

$7.02

Market Cap

318.7M

Sector

N/A

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$11.16

Market Cap

300.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUPX
SLN
Founded
2021
1994
Country
Singapore
United Kingdom
Employees
40
88
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
318.7M
300.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SUPX
SLN
Price
$7.02
$11.16
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$42.60
AVG Volume (30 Days)
152.6K
577.4K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.26
$4.19
52 Week High
$76.00
$11.90

Technical Indicators

Market Signals
Indicator
SUPX
SLN
Relative Strength Index (RSI) 37.57 61.95
Support Level N/A $5.87
Resistance Level $10.91 N/A
Average True Range (ATR) 0.53 0.82
MACD -0.06 0.02
Stochastic Oscillator 24.02 72.24

Price Performance

Historical Comparison
SUPX
SLN

About SUPX Super X AI Technology Limited Ordinary Shares

Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: